Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
The aim of this study was to assess the side effects and the efficacy of thalidomide alone or in combination with dexamethasone in relapsed multiple myeloma (MM) and to evaluate possible predictive factors for response rate and survival. Twenty-nine pretreated patients were enrolled, including 13 pa...
Main Authors: | Schütt, P, Ebeling, P, Buttkereit, U, Brandhorst, D, Opalka, B, Poser, M, Müller, S, Flasshove, M, Moritz, T, Seeber, S, Nowrousian, MR |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2005
|
Similar Items
-
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
by: Schütt, P, et al.
Published: (2005) -
In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
by: Schütt, P, et al.
Published: (2005) -
Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.
by: Schütt, P, et al.
Published: (2006) -
The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.
by: Schütt, P, et al.
Published: (2008) -
Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma
by: Nowrousian, MR, et al.
Published: (2005)